Tianjin Shengji Group Co., Ltd., established on 1998-10-21, Business scope includes technical services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Veterinary drug business;Disinfectant sales(Free of Hazardous Chemicals);Animal Husbandry and Fishery Feed Sales;Feed Additive Sales;fertilizer sales;Retailing of protective equipment for healthcare workers;Pet Food and Supplies Wholesale;Feed production special equipment sales;Refrigeration,Air Conditioning Equipment Sales;road freight transport(Does not contain dangerous goods)Non-residential real estate leases;property management;Machinery and Equipment Leasing;Car rental;Landscaping engineering construction;Import and export;Technology Import and Export;Grain Purchase;Purchase of primary agricultural products;Chinese herbal medicine acquisition.Limited to branch operations:Veterinary drug production;Disinfectant production(Free of Hazardous Chemicals);feed production;Feed additive production;Primary processing of non-edible agricultural products;fertilizer production;Manufacturing of bio-based materials.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

Virginia Tech Intellectual Properties, Inc. handles, protects and licenses technologies developed by the faculty, staff and students. It facilitates the licensing of technology to companies, encourages new faculty startup ventures, works with publishers and distributors of software, and supports the transfer of research and knowledge to other universities, research institutes and companies. The company was founded in 1985 and is headquartered in Blacksburg, VA.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Wellstat Therapeutics Corporation is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Dedicated to the discovery, development and commercialization of innovative therapeutics that expand the frontiers of medicine, Wellstat Therapeutics Corporation is committed to improving the lives of patients with chronic and life-threatening diseases.\nWellstat Therapeutics's focus is in the following fields:\nOncology\nMetabolic Diseases\nNeurodegenerative Diseases\nNeurometabolic Diseases\nWellstat Therapeutics is developing an extensive and diverse pipeline of novel small molecule therapeutic agents. The Company owns a broad patent portfolio covering this technology and is constantly expanding its intellectual property estate. Wellstat Therapeutics' pipeline spans the stages of development from discovery through Phase III clinical trials.\nWellstat Therapeutics was founded in 1985. The Company has a highly talented management team with significant experience in drug discovery, development, and commercialization. Samuel J. Wohlstadter, a company founder and the Chief Executive Officer was also a founder of Amgen Inc., Applied Biosystems (currently a division of Applera Corporation), IGEN International Inc. (currently a subsidiary of Roche), BioVeris Corporation (currently a subsidiary of Roche), and Hyperion Catalysis International, Inc.\nWellstat Therapeutics employs dedicated scientists, business professionals and support personnel at its state-of-the-art facilities in Gaithersburg, Maryland. Wellstat Therapeutics is part of the Wellstat Group of Companies, one of the largest and leading bioscience employers in the Baltimore-Washington Metropolitan Area. The Wellstat Group of Companies has expertise in all stages of discovery research and development, including:\nChemistry\nCell and Molecular Biology\nDisease Models\nTranslational Biology\nClinical Research and Development\nProject Management\nRegulatory Quality Assurance and Control\nManufacturing\nLegal and Financial

Manufactures pharmaceuticals

Guangdong Huamei Zhongyuan Biotechnology Co., Ltd., established on 2013-07-25, Business scope includes general items:Biochemical product technology research and development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products);Medical Research and Experimental Development;Machinery and Equipment Leasing;Cosmetics Retail;Cosmetics Wholesale;Development of Human Gene Diagnosis and Therapy Technology;Sales of Class I Medical Devices;Experimental analysis instrument sales;Drug testing equipment sales;Sales of formula food for special medical purposes;Healthy food(prepackaged)Sales;food sales(Only sell prepackaged food);Food Internet Sales(Only sell prepackaged food);internet sales(Except for products that require a license for sale);Health Consulting Services(Does not include medical services);Environmental Protection Monitoring.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Inspection and testing service;Forensic identification service;medical service;Labor dispatch service;pharmaceutical production;Production of formula food for special medical purpose.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

ratiopharm GmbH engages in the production and distribution of generic drugs and pharmaceutical products. It offers pain relievers, nasal sprays, bronchial drops, as well as medicines for treating high blood pressure, cancer, pulmonary arterial hypertension, human immunodeficiency virus infection and acquired immune deficiency syndrome. The company was founded in 1973 and is headquartered in Ulm, Germany.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Part of Merck KGaA, Merck & Cie KG is a company headquartered in Altdorf, Switzerland, that provides pharmaceutical preparation services.

Mebiol is a cultivation system which can produce high nutritious vegetables

The Boots Co. Plc owns and operates a chain of pharmaceutical and personal care retail stores. The firm’s stores are consists of local pharmacies, a healthcare-focused community stores; convenience and high-street stores offering pharmacy-led care. The company is headquartered in Nottingham, the United Kingdom.

MIBR is developing treatments and vaccines for rare diseases, autoimmune diseases, infectious diseases, cancers, etc. novel drug development using artificial intelligence pursuing the goals of developing new drugs and improving public health on a global scale

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.